Sleiman, J., Charabaty, A. and Rahman, A. ur (2021) “Do pharmacokinetics justify dose-optimization for loss of response to Vedolizumab in IBD?”, @Gijournal, 1(1). doi: 10.52697/gijournal.v1i1.23.